CA 125 is dominantly expressed by arrest of G0/G1 phase in uterine cervical adenocarcinoma cell line

Gynecologic Oncology

Volumn 71, Issue 3, 1998, Pages 442-449

  Hayashi, Takuhiro ^a   Hayakawa, Osamu ^a   Kudo, Ryuichi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

EID: 0032408277     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5179     Document Type: Article

References (32)

1. 1. Bast RC, Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epitherial ovarian cancer. N Engl J Med 309:883-887, 1983
2. 2. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr, Knapp RC, Bast RC, Jr: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057-1058, 1984
3. 3. Patsner B, Orr JW, Mann WJ, Jr: Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 162:427-429, 1990
4. 4. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE: Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 84:12-16, 1994
5. 5. Nakai T, Sakahara H, Endo K, Shirato M, Kobayashi H, Hosono M, Saga T, Sakamoto M, Konishi J: Changes in CA 125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells. Ann Nucl Med 7:133-139, 1993
6. 6. Marth C, Fuith LC, Böck G, Daxenbichler G, Dapunt O: Modulation of ovarian carcinoma tumor marker CA-125 by γ-interferon. Cancer Res 49:6538-6542, 1989
7. 7. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O: Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA 125. Gynecol Oncol 62:384-389, 1996
8. 8. Möbus VJ, Asphal W, Knapstein PG, Kreienberg R: Effects of interferon γ on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 120:27-34, 1993
9. 9. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E, Offner F, Feichtinger H, Zwierzina H, Daxenbichler G: Different effects of interferons, interleukin-1β and tumor necrosis factor-α in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67:826-830, 1996
10. WAF1/CIP1 mediated STAT1. Science 272:719-722, 1996
11. 11. Kobayashi H, Ida W, Terao T, Kawashima Y: Quantitative and qualitative assessment of CA-125 production by human endometrial epithelial cells: comparison of eutopic and heterotopic epithelial cells. Int J Cancer 54: 426-434, 1993
12. 12. Koizumi M, Uede T, Shijubo N, Kudo R, Hashimoto M, Kikuchi K: New monoclonal antibody, 1C5, reactive with human cervical adenocarcinoma of the uterus, with immunodiagnostic potential. Cancer Res 48:6565-6572, 1988
13. 13. Hayakawa O, Kudo R, Koizumi M, Yamauchi O, Yamamoto H, Takehara M: Establishment and characterization of a cell line derived from human uterine cervical adenocarcinoma and its chemosensitivity to anticancer drugs. Sapporo Med J 57:603-611, 1988
14. 14. Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK, Herberman RB: A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 20:193-197, 1985
15. 15. Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU: Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45:2866-2872, 1985
16. 16. van der Burg M, Edelstein M, Gerlis L, Liang CM, Hirschi M, Dawson A: Recombinant interferon-gamma (immuneron): results of a phase I trial in patients with cancer. J Biol Response Mod 4:264-272, 1985
17. 17. Freeman JW, McGrath P, Bondada V, Selliah N, Ownby M, Maloney T, Busch RK, Busch H: Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Res 51:1973-1978, 1991
18. 18. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
19. -/- mice. Cell 89:1011-1019, 1997
20. 20. Fried J, Perez AG, Clarkson BD: Flow cytofluorometric analysis of cell cycle distributions using propidium iodide. Properties of the method and mathematical analysis of the data. J Cell Biol 71:172-181, 1976
21. 21. Holford TR, Walter SD, Dunnett CW: Simultaneous interval estimates of the odds ratio in studies with two or more comparisons. J Clin Epidemiol 42:427-434, 1989
22. 22. Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A: Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci USA 89:402-406, 1992
23. 23. Vadiveloo PK, Vairo G, Novak U, Royston AK, Whitty G, Filonzi EL, Cragoe EJ, Jr, Hamilton JA: Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints. Oncogene 13:599-608, 1996
24. 24. Recombinant human interferon gamma (S-6810) research group on renal cell carcinoma: Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Cancer 60:929-933, 1987
25. 25. Friesel R, Komoriya A, Maciag T: Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 104:689-696, 1987
26. 26. Massad LS, Mutch DG, Powell CB, Kao MS, Collins JL: Expression of a resistance mechanism in ovarian and cervical carcinoma cells prevents their lysis by γ-interferon. Cancer Res 50:4923-4928, 1990
27. 27. Darnell JE, Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421, 1994
28. 28. Decker T, Lew DJ, Mirkovitch J, Darnell JE, Jr: Cytoplasmic activation of GAF, and IFN-γ-regulated DNA-binding factor. EMBO J 10:927-932, 1991
29. 29. Nakai T, Endo K, Hosono M, Saga T, Watanabe Y, Sakahara H, Imai K, Yachi A, Kiyozuka Y, Ishiwata I, Konishi J: Drug effects on CA 125 antigen expression and antibody binding to cancer cells. Int J Cancer 48:463-467, 1991
30. 30. Masuho Y, Zalutsky M, Knapp RC, Bast RC, Jr: Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 44:2813-2819, 1984
31. 31. Street D, Kaufmann AM, Vaughan A, Fisher SG, Hunter M, Schreckenberger C, Potkul RK, Gissmann L, Qiao L: Interferon-γ enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol 65:265-272, 1997
32. 32. Wu AJ, Kurrasch RH, Katz J, Fox PC, Baum BJ, Atkinson JC: Effect of tumor necrosis factor-α and interferon-γ on the growth of a human salivary grand cell line. J Cell Physiol 161:217-226, 1994